EA201400993A1 - ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION - Google Patents
ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATIONInfo
- Publication number
- EA201400993A1 EA201400993A1 EA201400993A EA201400993A EA201400993A1 EA 201400993 A1 EA201400993 A1 EA 201400993A1 EA 201400993 A EA201400993 A EA 201400993A EA 201400993 A EA201400993 A EA 201400993A EA 201400993 A1 EA201400993 A1 EA 201400993A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- active
- application
- growth factor
- antibodies against
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Предусмотрены модифицированные анти-EGFR антитела и молекулы нуклеиновой кислоты, кодирующие модифицированные анти-EGFR антитела. Также предусмотрены способы лечения и применения с использованием модифицированных анти-EGFR антител.Modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies are provided. Methods of treatment and use with modified anti-EGFR antibodies are also contemplated.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261685089P | 2012-03-08 | 2012-03-08 | |
PCT/US2013/030055 WO2013134743A1 (en) | 2012-03-08 | 2013-03-08 | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201400993A1 true EA201400993A1 (en) | 2015-05-29 |
Family
ID=47892080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201400993A EA201400993A1 (en) | 2012-03-08 | 2013-03-08 | ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140170159A9 (en) |
EP (2) | EP3296320A1 (en) |
JP (2) | JP6181089B2 (en) |
KR (2) | KR20170036142A (en) |
CN (1) | CN104379602B (en) |
AU (1) | AU2013229786B2 (en) |
BR (1) | BR112014022228A2 (en) |
CA (1) | CA2866612C (en) |
EA (1) | EA201400993A1 (en) |
HK (1) | HK1203972A1 (en) |
MX (1) | MX2014010750A (en) |
NZ (1) | NZ630020A (en) |
SG (1) | SG11201405553YA (en) |
WO (1) | WO2013134743A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI395593B (en) | 2008-03-06 | 2013-05-11 | Halozyme Inc | In vivo temporal control of activatable matrix-degrading enzymes |
CN103201293B (en) | 2010-09-08 | 2016-04-27 | 哈洛齐梅公司 | The method of assessment and qualification or development condition active therapeutic protein |
EP2976622B1 (en) * | 2013-03-14 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Protein standard |
CN105764924A (en) * | 2013-09-12 | 2016-07-13 | 哈洛齐梅公司 | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
TW201609805A (en) * | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | Multifunctional antibodies binding to EGFR and MET |
CN103675262A (en) * | 2013-12-27 | 2014-03-26 | 步荣发 | Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma |
MX2016014824A (en) * | 2014-05-13 | 2017-03-23 | Bioatla Llc | Conditionally active biological proteins. |
PT3148581T (en) * | 2014-05-30 | 2020-01-06 | Henlix Biotech Co Ltd | Anti-epidermal growth factor receptor (egfr) antibodies |
CN107074975A (en) * | 2014-08-28 | 2017-08-18 | 生物蛋白有限公司 | Condition active chimeric antigen receptor for the T cell of modification |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
EP3189152A4 (en) | 2014-09-03 | 2018-04-04 | BioAtla LLC | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
CN114732916B (en) * | 2014-09-11 | 2023-12-19 | 西雅图基因公司 | Targeted delivery of tertiary amine-containing drug substances |
PL3110447T3 (en) | 2014-09-16 | 2020-10-19 | Synermore Biologics Co., Ltd. | Anti-egfr antibody and uses of same |
JP6625627B2 (en) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using the same |
MX2017010795A (en) | 2015-02-24 | 2018-04-11 | Bioatla Llc | Conditionally active biological proteins. |
EP3270965B1 (en) * | 2015-03-18 | 2020-05-06 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
KR101770559B1 (en) * | 2015-04-23 | 2017-08-24 | 신일제약주식회사 | Fragment Antigen Binding Specifically Binding to Epidermal Growth Factor Receptor |
US20160343140A1 (en) * | 2015-05-24 | 2016-11-24 | Pointivo, Inc. | Surveying and measurement methods and devices |
KR20240042137A (en) * | 2015-07-24 | 2024-04-01 | 글리크닉 인코포레이티드 | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding |
JP7064769B2 (en) * | 2015-11-02 | 2022-05-11 | バイオアトラ、エルエルシー | Conditionally active polypeptide |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
AU2017207263B2 (en) * | 2016-01-12 | 2021-01-07 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
ES2947230T3 (en) * | 2016-03-22 | 2023-08-03 | Hoffmann La Roche | Bispecific molecules for protease-activated T lymphocytes |
KR102128556B1 (en) * | 2016-04-27 | 2020-06-30 | 주식회사 녹십자 | Pharmaceutical composition for inhibiting metastasis of cancer comprising an antibody that specifically binds to the epidermal growth factor receptor |
IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
US11034775B2 (en) | 2016-06-07 | 2021-06-15 | Gliknik Inc. | Cysteine-optimized stradomers |
CN111201038A (en) | 2017-01-11 | 2020-05-26 | 戊瑞治疗有限公司 | PSGL-1 antagonists and uses thereof |
US11603406B2 (en) * | 2017-03-14 | 2023-03-14 | Five Prime Therapeutics, Inc. | Antibodies binding to VISTA at acidic pH |
CA3073766A1 (en) | 2017-09-08 | 2019-03-14 | Seattle Genetics, Inc. | Process for the preparation of tubulysins and intermediates thereof |
WO2019062755A1 (en) * | 2017-09-29 | 2019-04-04 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against EGFR and PD-1 |
KR20200058540A (en) | 2017-10-02 | 2020-05-27 | 비스테라, 인크. | Antibody molecules against CD138 and uses thereof |
CU24558B1 (en) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | MONOCLONAL ANTIBODIES RECOGNIZING THE EPIDERMAL GROWTH FACTOR RECEPTOR AND ITS DERIVED FRAGMENTS |
CN109134654B (en) * | 2018-08-02 | 2021-08-03 | 广东药科大学 | Single-chain antibody targeting EGFR dimerization interface and application thereof |
BR112021002432A2 (en) * | 2018-08-13 | 2021-05-04 | Regeneron Pharmaceuticals, Inc. | therapeutic protein selection under simulated in vivo conditions |
CN112289369B (en) * | 2020-12-15 | 2021-04-02 | 武汉华美生物工程有限公司 | Antibody library construction method and device based on deep learning |
EP4356926A1 (en) * | 2021-06-14 | 2024-04-24 | Centro de Inmunologia Molecular | Use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of patients with acute hypoxaemic respiratory failure |
WO2023097254A1 (en) * | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US5175269A (en) | 1984-01-30 | 1992-12-29 | Enzo Diagnostics, Inc. | Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
CA1289880C (en) | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
US4956453A (en) | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
DE3600905A1 (en) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5082927A (en) | 1986-09-24 | 1992-01-21 | The United States Of America As Represented By The Department Of Health And Human Services | Selectively cytotoxic IL-4-PE40 fusion protein |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4920143A (en) | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5109016A (en) | 1988-05-23 | 1992-04-28 | Georgia State University Foundation, Inc. | Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions |
US5192788A (en) | 1988-05-23 | 1993-03-09 | Georgia State University Foundation, Inc. | Porphyrin antiviral compositions |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US4968715A (en) | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
US5093349A (en) | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5028594A (en) | 1988-12-27 | 1991-07-02 | Naxcor | Use of photodynamic compositions for cytotoxic effects |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5237016A (en) | 1989-01-05 | 1993-08-17 | Siska Diagnostics, Inc. | End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids |
US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5252720A (en) | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
US5149708A (en) | 1989-06-07 | 1992-09-22 | University Of British Columbia | Photosensitizing Diels-Alder porphyrin derivatives |
US5144019A (en) | 1989-06-21 | 1992-09-01 | City Of Hope | Ribozyme cleavage of HIV-I RNA |
US5272262A (en) | 1989-06-21 | 1993-12-21 | City Of Hope | Method for the production of catalytic RNA in bacteria |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5218088A (en) | 1989-11-02 | 1993-06-08 | Purdue Research Foundation | Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates |
JP2571874B2 (en) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Protein microsphere composition |
US5087636A (en) | 1990-02-20 | 1992-02-11 | University Of British Columbia | Method to destroy malignant cells in mononuclear cell populations |
US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
US5053423A (en) | 1990-03-22 | 1991-10-01 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
US5238940A (en) | 1990-03-22 | 1993-08-24 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5217966A (en) | 1990-09-13 | 1993-06-08 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5202317A (en) | 1990-09-13 | 1993-04-13 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
DE122004000008I1 (en) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanized heregulin antibody. |
WO1993001286A2 (en) | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
EP0594749A1 (en) | 1991-07-15 | 1994-05-04 | Repligen Corporation | Modified pf4 compositions and methods of use |
WO1993003709A1 (en) | 1991-08-16 | 1993-03-04 | Vical, Inc. | Composition and method for treating cystic fibrosis |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
ATE295420T1 (en) | 1992-02-06 | 2005-05-15 | Chiron Corp | MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5257970A (en) | 1992-04-09 | 1993-11-02 | Health Research, Inc. | In situ photodynamic therapy |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
JP3794701B2 (en) | 1994-07-21 | 2006-07-12 | アクゾ ノーベル ナムローゼ フェンノートシャップ | Cyclic ketone peroxide formulation |
AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5622958A (en) | 1994-12-01 | 1997-04-22 | Sloan-Kettering Institute For Cancer Research | Enediyne quinone imines and methods of preparation and use thereof |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US5840300A (en) | 1995-09-11 | 1998-11-24 | Trustees Of The University Of Pennsylvania | Methods and compositions comprising single chain recombinant antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
BR9708640B1 (en) | 1996-04-12 | 2013-06-11 | irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them. | |
JP4203835B2 (en) | 1996-08-19 | 2009-01-07 | アメリカ合衆国 | Novel liposomal complexes that increase systemic delivery |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (en) | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
JP2005511627A (en) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | Treatment of immunological diseases using anti-CD30 antibodies |
US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
WO2005056606A2 (en) | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
EP1511861A4 (en) * | 2002-06-12 | 2007-12-05 | Genencor Int | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
FR2846869B1 (en) | 2002-11-08 | 2005-02-18 | Scient X | TIGHTENING NUT FOR OSTEOSYNTHESIS DEVICE |
CN1913913A (en) * | 2003-12-12 | 2007-02-14 | 金克克国际有限公司 | CAB molecules |
US20110160440A1 (en) * | 2003-12-12 | 2011-06-30 | Genencor International, Inc. | Cab Molecules |
NZ549393A (en) | 2004-01-23 | 2009-07-31 | Cornell Res Foundation Inc | Methods for reducing oxidative damage |
MXPA06010715A (en) | 2004-03-19 | 2007-05-23 | Imclone Systems Inc | Human anti-epidermal growth factor receptor antibody. |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
MXPA06014065A (en) | 2004-06-01 | 2007-01-31 | Genentech Inc | Antibody drug conjugates and methods. |
US20110142822A1 (en) | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
PT1951759E (en) | 2005-11-12 | 2010-04-01 | Lilly Co Eli | Anti-egfr antibodies |
EP2441770A1 (en) | 2006-02-10 | 2012-04-18 | The University of Cincinnati | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
WO2008152537A2 (en) | 2007-06-14 | 2008-12-18 | Zenotech Laboratories Limited | Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof |
JP5095446B2 (en) | 2008-03-05 | 2012-12-12 | 矢崎総業株式会社 | connector |
JP5470817B2 (en) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | Battery electrode, battery using the same, and manufacturing method thereof |
NO2842575T3 (en) | 2008-03-18 | 2018-02-24 | ||
CN101584696A (en) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | Composition containing quinazoline derivatives, preparation method and use |
CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
WO2010080463A1 (en) | 2008-12-18 | 2010-07-15 | Imclone Llc | Antibody humanization |
CA2777825A1 (en) | 2009-10-28 | 2011-05-19 | Abbott Biotherapeutics Corp. | Anti-egfr antibodies and their uses |
JP6046494B2 (en) | 2010-02-08 | 2016-12-14 | アジェンシス,インコーポレイテッド | Antibody drug conjugate (ADC) that binds to 161P2F10B protein |
US8071093B1 (en) | 2010-05-17 | 2011-12-06 | Samsung Electronics Co., Ltd. | Fully human anti-epidermal growth factor receptor antibodies |
CA2803188A1 (en) | 2010-07-09 | 2012-01-12 | Antonello Pessi | Lipid-conjugated antibodies |
CN103025760A (en) | 2010-08-10 | 2013-04-03 | 葛莱高托普有限公司 | Humanized EGFR antibodies |
CN103201293B (en) * | 2010-09-08 | 2016-04-27 | 哈洛齐梅公司 | The method of assessment and qualification or development condition active therapeutic protein |
JP6136279B2 (en) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | Rolling bearing device |
TWI503850B (en) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | Over-current protection device |
TWI510996B (en) | 2013-10-03 | 2015-12-01 | Acer Inc | Methods for controlling a touch panel and portable computers using the same |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2013
- 2013-03-08 SG SG11201405553YA patent/SG11201405553YA/en unknown
- 2013-03-08 CN CN201380024291.1A patent/CN104379602B/en not_active Expired - Fee Related
- 2013-03-08 CA CA2866612A patent/CA2866612C/en not_active Expired - Fee Related
- 2013-03-08 EA EA201400993A patent/EA201400993A1/en unknown
- 2013-03-08 MX MX2014010750A patent/MX2014010750A/en unknown
- 2013-03-08 WO PCT/US2013/030055 patent/WO2013134743A1/en active Application Filing
- 2013-03-08 KR KR1020177008176A patent/KR20170036142A/en not_active Application Discontinuation
- 2013-03-08 KR KR1020147028274A patent/KR101721678B1/en active IP Right Grant
- 2013-03-08 NZ NZ630020A patent/NZ630020A/en not_active IP Right Cessation
- 2013-03-08 EP EP17194775.7A patent/EP3296320A1/en not_active Withdrawn
- 2013-03-08 US US13/815,553 patent/US20140170159A9/en not_active Abandoned
- 2013-03-08 BR BR112014022228A patent/BR112014022228A2/en not_active IP Right Cessation
- 2013-03-08 AU AU2013229786A patent/AU2013229786B2/en not_active Ceased
- 2013-03-08 JP JP2014561177A patent/JP6181089B2/en not_active Expired - Fee Related
- 2013-03-08 EP EP13710278.6A patent/EP2822970A1/en not_active Withdrawn
-
2015
- 2015-05-08 HK HK15104386.7A patent/HK1203972A1/en unknown
-
2017
- 2017-07-19 JP JP2017140087A patent/JP2017214412A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013134743A1 (en) | 2013-09-12 |
MX2014010750A (en) | 2015-02-05 |
KR20170036142A (en) | 2017-03-31 |
AU2013229786A1 (en) | 2014-09-25 |
JP6181089B2 (en) | 2017-08-16 |
HK1203972A1 (en) | 2015-11-06 |
BR112014022228A2 (en) | 2017-07-11 |
NZ630020A (en) | 2016-08-26 |
AU2013229786B2 (en) | 2017-06-22 |
CN104379602A (en) | 2015-02-25 |
EP2822970A1 (en) | 2015-01-14 |
KR101721678B1 (en) | 2017-03-31 |
WO2013134743A9 (en) | 2014-07-24 |
US20140170159A9 (en) | 2014-06-19 |
JP2015510761A (en) | 2015-04-13 |
CA2866612A1 (en) | 2013-09-12 |
JP2017214412A (en) | 2017-12-07 |
EP3296320A1 (en) | 2018-03-21 |
CN104379602B (en) | 2017-05-03 |
CA2866612C (en) | 2018-01-16 |
SG11201405553YA (en) | 2014-11-27 |
KR20140130749A (en) | 2014-11-11 |
US20130266579A1 (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201400993A1 (en) | ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION | |
EA201600252A1 (en) | MODIFIED ANTIBODIES TO RECEPTORS OF ANTIEPIDERMAL GROWTH FACTOR AND METHODS FOR THEIR USE | |
AR090903A1 (en) | ANTI-PMEL ANTIBODIES AND IMMUNOCADES17 | |
EA201591430A1 (en) | COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN | |
EA201491947A1 (en) | ANTIBODIES AND IMMUNOCONJUGATES TO LY6E AND METHODS OF APPLICATION | |
EA201591427A1 (en) | COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN | |
EA201591426A1 (en) | COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN | |
PH12015500114A1 (en) | HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF | |
EA201890729A1 (en) | ADJUSTABLE OPTIONS OF DOMAINS OF THE SUPERFAMINATION OF IMMUNOGLOBULINS AND THERAPY WITH CONSTRUCTED CELLS | |
EA201591432A1 (en) | COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN | |
EA201390575A1 (en) | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | |
EA201590993A1 (en) | HETERODIMERNY IMMUNOHLOBULINS | |
TN2014000438A1 (en) | Anti-fcrn antibodies | |
BR112013021134A2 (en) | modulators and methods of use | |
EA201491811A1 (en) | ANTI-LgR5 ANTIBODIES AND IMMUNOCONJUGATES | |
PH12014502179B1 (en) | Ang2-binding molecules | |
EA201390472A1 (en) | NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES | |
MX341578B (en) | Treatment of osteoarthritis and pain. | |
EA201270722A1 (en) | RIFAXIMINE FORMS AND THEIR APPLICATION | |
EA201290590A1 (en) | MODIFIED TUBERCULOSIS ANTIGENS | |
EA201300819A1 (en) | ANTIBODY MOLECULES THAT ASSOCIATE WITH IL-17A AND IL-17F | |
EA201992707A1 (en) | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION | |
EA201790032A1 (en) | BICYCLICALLY SUBSTITUTED URACILES AND THEIR APPLICATION | |
MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
PH12016500753A1 (en) | Antibodies specific to fcrn |